Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|E3F05||ECOG||Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-10501||CALGB||A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease <br>||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5152||ECOG-ACRIN||A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5161||ECOG-ACRIN||Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|PBTC-055||PBTC||Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults||Pediatric CIRB||Available to Open|
|9876||ETCTN||Phase 1b Study of HSP90 Inhibitor; AT13387 in Combination with Paclitaxel in Patients with Advanced; Triple Negative Breast Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|AALL15P1||COG||A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND#TBD; NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A Gene Rearrangement||Pediatric CIRB||Available to Open|
|N0147||NCCTG||A Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|ABTC-1804||ABTC||Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0262||GOG||GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865; IND #113912) in the Treatment of Primary Stage II; III OR IV Epithelial Ovarian; Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262||Adult CIRB - Late Phase Emphasis||Available to Open|